시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 소포성 모노아민 수송체 2(VMAT2) 억제제 시장 보고서(2025년)
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Global Market Report 2025
상품코드 : 1720924
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

소포성 모노아민 수송체 2(VMAT2) 억제제 시장 규모는 향후 수년간 급성장이 전망됩니다. 역사적인 기간 동안의 성장은 운동 장애의 유병률 증가, 효과적인 치료 옵션에 대한 수요 증가, 지각 운동 장애에 대한 인식 증가, 노인 인구 증가, 경구용 제형에 대한 선호도 증가에 기인할 수 있습니다.

파킨슨병의 유병률 증가는소포성 모노아민 수송체 2(VMAT2) 억제제 시장의 확대를 촉진할 것으로 예측됩니다. 파킨슨병의 유병률 증가는 주로 인구 고령화, 진단 개선, 독소 노출과 같은 환경적 요인, 유전적 요인, 그리고 질병에 대한 인식 증가에 기인합니다. 2022년 12월 미국 파킨슨병 재단(Parkinson's Foundation)은 미국에서 약 9만명이 파킨슨병으로 진단되었다고 보고했는데, 이는 기존의 추정 연간 진단수 6만명에 비해 50% 증가했습니다.

VMAT2 억제제 시장의 주요 기업은 환자의 컴플라이언스를 개선하고 약물의 안정성을 높이고 치료 결과를 최적화하기 위해 캡슐과 같은 혁신적인 제형의 개발에 주력하고 있습니다. 투여, 약물 안정성 향상, 환자 복용 어드히어런스 지원으로 VMAT2 억제제에 이익을 제공합니다. Sprinkle(바르베나진) 캡슐을 출시했습니다. Sprinkle은 "Ingrezza"와 유사한 효과적인 복용 방법을 제공하지만 부드러운 음식에 뿌려 복용하거나 캡슐 당 삼킬 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that blocks VMAT2, a protein responsible for transporting monoamines such as dopamine, serotonin, and norepinephrine into synaptic vesicles for release in the brain. These inhibitors are used to manage neurological and psychiatric disorders by reducing excessive neurotransmitter release, particularly dopamine, and are effective in treating conditions such as tardive dyskinesia, Huntington's disease, and other hyperkinetic movement disorders.

The main drugs in the VMAT2 inhibitor category include tetrabenazine, deutetrabenazine, valbenazine, and others. Tetrabenazine is a well-known VMAT2 inhibitor that treats movement disorders by lowering dopamine levels in the brain. These medications are administered via various routes, including oral and other methods, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used for various conditions such as Huntington's disease, tardive dyskinesia, and other movement disorders. The primary end users of these drugs include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vesicular monoamine transporter 2 (VMAT2) inhibitor market statistics, including the vesicular monoamine transporter 2 (VMAT2) inhibitor industry global market size, regional shares, competitors with the vesicular monoamine transporter 2 (VMAT2) inhibitor market share, detailed vesicular monoamine transporter 2 (VMAT2) inhibitor market segments, market trends, and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (VMAT2) inhibitor industry. This vesicular monoamine transporter 2 (VMAT2) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size has grown rapidly in recent years. It will grow from $1.13 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the rising prevalence of movement disorders, an increasing demand for effective treatment options, greater awareness of tardive dyskinesia, a growing geriatric population, and a higher preference for oral formulations.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The projected growth in the forecast period can be attributed to the rising incidence of neurodegenerative diseases, a growing adoption of targeted therapies, an increasing focus on personalized medicine, more investment in research and development, and heightened awareness of psychiatric and movement disorders. Key trends during this period include advancements in neurological research, improvements in drug formulations, a shift toward personalized and precision medicine, the development of next-generation VMAT2 inhibitors, and the integration of digital health technologies.

The growing prevalence of Parkinson's disease is expected to drive the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market. Parkinson's disease is a progressive neurological disorder that impairs movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of Parkinson's is primarily attributed to an aging population, improved diagnosis, environmental factors such as exposure to toxins, genetic factors, and increased awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by regulating dopamine release, reducing tremors, and controlling dyskinesia. For example, in December 2022, the Parkinson's Foundation reported that nearly 90,000 people were diagnosed with Parkinson's disease in the U.S., a 50% increase compared to the previous estimate of 60,000 annual diagnoses. As a result, the rising prevalence of Parkinson's disease is propelling the growth of the VMAT2 inhibitor market.

Leading companies in the VMAT2 inhibitor market are focusing on developing innovative formulations such as capsules to improve patient compliance, enhance drug stability, and optimize therapeutic outcomes. Capsules, which are solid dosage forms enclosed in gelatin or HPMC shells, benefit VMAT2 inhibitors by ensuring precise dosing, improving drug stability, and supporting patient adherence. For example, in July 2024, Neurocrine Biosciences Inc. launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza. This version is designed to facilitate administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who have difficulty swallowing. Ingrezza Sprinkle provides the same effective dosing options as Ingrezza but can be taken by sprinkling the contents onto soft food or swallowing the capsule whole.

In March 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition enables Bristol Myers Squibb to enhance its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline, including the VMAT2 inhibitor KarXT. KarXT has the potential to address unmet needs in psychiatric disorders such as schizophrenia, expanding Bristol Myers Squibb's therapeutic offerings and accelerating its growth in the neuroscience sector. Karuna Therapeutics is a U.S.-based biopharmaceutical company that specializes in VMAT2 inhibitor treatments.

Major players in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH.

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in vesicular monoamine transporter 2 (VMAT2) inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vesicular monoamine transporter 2 (vmat2) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vesicular monoamine transporter 2 (vmat2) inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vesicular monoamine transporter 2 (vmat2) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Characteristics

3. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Trends And Strategies

4. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Growth Analysis And Strategic Analysis Framework

6. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segmentation

7. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Regional And Country Analysis

8. Asia-Pacific Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

9. China Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

10. India Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

11. Japan Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

12. Australia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

13. Indonesia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

14. South Korea Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

15. Western Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

16. UK Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

17. Germany Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

18. France Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

19. Italy Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

20. Spain Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

21. Eastern Europe Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

22. Russia Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

23. North America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

24. USA Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

25. Canada Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

26. South America Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

27. Brazil Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

28. Middle East Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

29. Africa Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

30. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Landscape And Company Profiles

31. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Other Major And Innovative Companies

32. Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

34. Recent Developments In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

35. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기